ADLM Says FDA’s LDT Final Rule Will Impede Fight Against Drug Epidemic
An ADLM survey found that the FDA’s LDT final rule will likely reduce patient access to crucial tests, despite exemptions to mitigate this.
Read MorePosted by Andy Lundin | Jun 27, 2024 | Compliance |
An ADLM survey found that the FDA’s LDT final rule will likely reduce patient access to crucial tests, despite exemptions to mitigate this.
Read MorePosted by Chris Wolski | Jun 26, 2024 | Womens Health |
Recent advancements in congenital CMV (cCMV) screening underscore the need for enhanced awareness and legislative action.
Read MorePosted by Andy Lundin | Jun 20, 2024 | Cancer |
A new study reveals that AI can detect and diagnose cancer from tissue samples with 98.2% accuracy, allowing for earlier treatment.
Read MorePosted by Andy Lundin | Jun 19, 2024 | Sequencing Systems, Unknown Origin & Other Cancer Types |
A new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read MorePosted by Chris Wolski | Jun 18, 2024 | Dementias & Alzheimer’s |
A study has demonstrated that blood markers can identify frontotemporal dementia (FTD), (ALS), and progressive supranuclear palsy (PSP).
Read More